Загрузка...
Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
Even though classical Hodgkin lymphoma is highly curable, the outcome of patients with a refractory or relapsed disease has been disappointing. Multiple lines of therapy are available for patients after their first failure, and most respond to subsequent therapies. However, there is a sizable propor...
Сохранить в:
| Опубликовано в: : | World J Oncol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elmer Press
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8297052/ https://ncbi.nlm.nih.gov/pubmed/34349851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/wjon1388 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|